These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32451342)

  • 81. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.
    Nakamura M; Nagamine T
    Psychiatry Clin Neurosci; 2017 Dec; 71(12):844. PubMed ID: 28945327
    [No Abstract]   [Full Text] [Related]  

  • 82. Eszopiclone (lunesta) for treatment of insomnia.
    Laustsen G
    Nurse Pract; 2005 Sep; 30(9):67-8. PubMed ID: 16151317
    [No Abstract]   [Full Text] [Related]  

  • 83. Lunesta for the treatment of insomnia.
    Lajiness MJ
    Urol Nurs; 2008 Apr; 28(2):134-5. PubMed ID: 18488591
    [No Abstract]   [Full Text] [Related]  

  • 84. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
    Pałasz A; Lapray D; Peyron C; Rojczyk-Gołębiewska E; Skowronek R; Markowski G; Czajkowska B; Krzystanek M; Wiaderkiewicz R
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):157-68. PubMed ID: 23702225
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Insomnia. Safe and effective therapy for sleep problems in the older patient.
    Schneider DL
    Geriatrics; 2002 May; 57(5):24-6, 29, 32 passim. PubMed ID: 12040591
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment of sleep-maintenance insomnia in older adults: sleep period reduction, sleep education, and modified stimulus control.
    Hoelscher TJ; Edinger JD
    Psychol Aging; 1988 Sep; 3(3):258-63. PubMed ID: 3268267
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Anxiolytic effects of a new triazolobenzodiazepine, U-31,889.
    Itil TM; Polvan N; Egilmez S; Saletu B; Marasa J
    Curr Ther Res Clin Exp; 1973 Sep; 15(9):603-15. PubMed ID: 4201544
    [No Abstract]   [Full Text] [Related]  

  • 89. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia.
    Morin CM; Bastien C; Guay B; Radouco-Thomas M; Leblanc J; Vallières A
    Am J Psychiatry; 2004 Feb; 161(2):332-42. PubMed ID: 14754783
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis.
    Wang X; Fan X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
    Int J Antimicrob Agents; 2019 Dec; 54(6):780-789. PubMed ID: 31284039
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
    Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
    J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
    Sateia MJ; Buysse DJ; Krystal AD; Neubauer DN; Heald JL
    J Clin Sleep Med; 2017 Feb; 13(2):307-349. PubMed ID: 27998379
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Daridorexant Hydrochloride.
    Am J Health Syst Pharm; 2022 Jul; 79(15):1215-1217. PubMed ID: 35661196
    [No Abstract]   [Full Text] [Related]  

  • 95. Potential Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link.
    Palagini L; Geoffroy PA; Micoulaud-Franchi JA; Gemignani A; Riemann D
    J Clin Psychiatry; 2023 Jul; 84(4):. PubMed ID: 37428090
    [No Abstract]   [Full Text] [Related]  

  • 96. Correction to: Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):291. PubMed ID: 36826776
    [No Abstract]   [Full Text] [Related]  

  • 97. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
    Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
    ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
    Berger B; Brooks S; Zuiker R; Richard M; Muehlan C; Dingemanse J
    CNS Drugs; 2020 Dec; 34(12):1253-1266. PubMed ID: 33205362
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.